Recognizing the significant impact of the cGAS-STING pathway on inflammation and fibrosis in NAFLD/NASH, targeting this pathway to inhibit its activity has emerged as a hopeful therapeutic strategy. The gene discussed is STING1; the disease is metabolic dysfunction-associated steatotic liver disease.